Pharsight

Adempas is owned by Bayer Hlthcare.

Adempas contains Riociguat.

Adempas has a total of 3 drug patents out of which 0 drug patents have expired.

Adempas was authorised for market use on 08 October, 2013.

Adempas is available in tablet;oral dosage forms.

Adempas can be used as treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (cteph), (who group 4) after surgical treatment, or inoperable cteph, to improve exercise capacity and who functional class; treatment of adults with pulmonary hypertension (pah), (who group 1), to improve exercise capacity, who functional class and to delay clinical worsening.

The generics of Adempas are possible to be released after 18 February, 2034.

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7173037	BAYER HLTHCARE	Carbamate-substituted pyrazolopyridines	Dec, 2026 (3 years from now)
US10662188	BAYER HLTHCARE	Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate	Feb, 2034 (10 years from now)
US11203593	BAYER HLTHCARE	Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate	Feb, 2034 (10 years from now)

Do you want to check out ADEMPAS patents from before 2022?

Drugs and Companies using RIOCIGUAT ingredient

Market Authorisation Date: 08 October, 2013

Treatment: Treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (cteph), (who group 4) after surgical treatment, or inoperable cteph, to improve exercise capacity and who f...

Dosage: TABLET;ORAL